Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/10495/20366| Título : | Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions |
| Autor : | Syro Moreno, Luis Vicente Rotondo, Fabio Camargo Guerrero, Mauricio Ortíz Gómez, León Darío Serna Ortíz, Carlos Andrés Kovacs, Kalman |
| metadata.dc.subject.*: | Agentes alquilantes Alkylating Agents Antineoplastic Agents Antineoplásicos Reparación del ADN DNA Repair Neoplasias Neoplasms Tumores Neuroendocrinos Neuroendocrine Tumors O(6)-Methylguanine-DNA Methyltransferase O(6)-Metilguanina-ADN Metiltransferasa Neoplasias Hipofisarias Pituitary Neoplasms Temozolomida Temozolomide Metiltransferasa Methyltransferases Quimioterapia Chemotherapy |
| Fecha de publicación : | 2018 |
| Editorial : | Frontiers Media |
| Resumen : | ABSTRACT: Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. |
| metadata.dc.identifier.eissn: | 1664-2392 |
| metadata.dc.identifier.doi: | 10.3389/fendo.2018.00318 |
| metadata.dc.identifier.url: | https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full |
| Aparece en las colecciones: | Artículos de Revista en Ciencias Exactas y Naturales |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| CamargoMauricio_2018_TomozolomidePituitaryTumors.pdf | Artículo de revisión | 1.54 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons
